CC-2069: A Pan-Genotypic Preclinical NS5A Inhibitor

CC-2069 is a novel highly potent, pan-genotypic, NS5A inhibitor that produces an active metabolite (also a pM HCV inhibitor).

CC-2069 is an excellent combination drug candidate with Nuc and/or NNI.

CC-2069 Activity Profile Against NS5A Drug Resistant Variants

  • Showed excellent potency against NS5A drug resistant variants
  • Showed acceptable cytotoxicity profile with high therapeutic index

CC-2069 Status

  • Preclinical characterization is ongoing
  • Phase 1 study scheduled for 2017
Viral Disease Lead Discovery Lead Optimization Preclinical Regulatory Filing Phase 1
Hepatitis C CC-2069 (NS5A)
Lead Discovery Phase complete
Lead Optimization Phase complete
Preclinical Phase in progress
Regulatory Filing Phase not started
Phase 1 Phase not started